A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy
Future Cardiology | December 12, 2025 | Volume: 21 | Issue: 12 | Pages: 1017-1025
10.1080/14796678.2025.2591426
| PMID 41384357